Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report

Savolitinib is a tyrosine kinase inhibitor being developed for the treatment of metastatic non–small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) factor exon 14 skipping alterations. However, the role of savolitinib in neoadjuvant therapy for lung cancer remains unclear. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Zhang, Hao, Wang, Hanqing, Zeng, Jingtong, Zhang, Bo, Zhou, Ning, Zu, Lingling, Song, Zuoqing, Wang, Changli, Xu, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514319/
https://www.ncbi.nlm.nih.gov/pubmed/36176406
http://dx.doi.org/10.3389/fonc.2022.968030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514319/
https://www.ncbi.nlm.nih.gov/pubmed/36176406
http://dx.doi.org/10.3389/fonc.2022.968030

Ejemplares similares